186 related articles for article (PubMed ID: 17009082)
1. Japanese subpopulation analysis of the RENAAL, the landmark trial, is welcomed by our society.
Kimura G
Clin Exp Nephrol; 2006 Sep; 10(3):226-7. PubMed ID: 17009082
[No Abstract] [Full Text] [Related]
2. Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study.
Kurokawa K; Chan JC; Cooper ME; Keane WF; Shahinfar S; Zhang Z
Clin Exp Nephrol; 2006 Sep; 10(3):193-200. PubMed ID: 17009077
[TBL] [Abstract][Full Text] [Related]
3. Losartan in diabetic nephropathy.
Perico N; Ruggenenti P; Remuzzi G
Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
[TBL] [Abstract][Full Text] [Related]
4. Losartan: lessons learned from the RENAAL study.
Shahinfar S; Lyle PA; Zhang Z; Keane WF; Brenner BM
Expert Opin Pharmacother; 2006 Apr; 7(5):623-30. PubMed ID: 16553578
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes.
Winkelmayer WC; Zhang Z; Shahinfar S; Cooper ME; Avorn J; Brenner BM
Diabetes Care; 2006 Oct; 29(10):2210-7. PubMed ID: 17003295
[TBL] [Abstract][Full Text] [Related]
6. Renin angiotensin system blockade and nephropathy: why is it being called into question, and should it be?
Hollenberg NK; Epstein M
Clin J Am Soc Nephrol; 2006 Sep; 1(5):1046-8. PubMed ID: 17699325
[No Abstract] [Full Text] [Related]
7. Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study.
Shahinfar S; Dickson TZ; Ahmed T; Zhang Z; Ramjit D; Smith RD; Brenner BM;
Kidney Int Suppl; 2002 Dec; (82):S64-7. PubMed ID: 12410858
[TBL] [Abstract][Full Text] [Related]
8. The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes.
Mohanram A; Zhang Z; Shahinfar S; Lyle PA; Toto RD
Kidney Int; 2008 Mar; 73(5):630-6. PubMed ID: 18094675
[TBL] [Abstract][Full Text] [Related]
9. Aliskiren and dual therapy in type 2 diabetes mellitus.
Ingelfinger JR
N Engl J Med; 2008 Jun; 358(23):2503-5. PubMed ID: 18525047
[No Abstract] [Full Text] [Related]
10. Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union.
Gerth WC; Remuzzi G; Viberti G; Hannedouche T; Martinez-Castelao A; Shahinfar S; Carides GW; Brenner B
Kidney Int Suppl; 2002 Dec; (82):S68-72. PubMed ID: 12410859
[TBL] [Abstract][Full Text] [Related]
11. The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy.
Carides GW; Shahinfar S; Dasbach EJ; Keane WF; Gerth WC; Alexander CM; Herman WH; Brenner BM;
Pharmacoeconomics; 2006; 24(6):549-58. PubMed ID: 16761903
[TBL] [Abstract][Full Text] [Related]
12. Renin angiotensin system (RAS) blockade and diabetic microvascular complications in the eye and kidney.
Bilous R
Prim Care Diabetes; 2008 Dec; 2(4):201-2. PubMed ID: 18760685
[No Abstract] [Full Text] [Related]
13. Advances in the treatment of diabetic renal disease: focus on losartan.
Rayner B
Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
[TBL] [Abstract][Full Text] [Related]
14. Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study.
Chan JC; Wat NM; So WY; Lam KS; Chua CT; Wong KS; Morad Z; Dickson TZ; Hille D; Zhang Z; Cooper ME; Shahinfar S; Brenner BM; Kurokawa K;
Diabetes Care; 2004 Apr; 27(4):874-9. PubMed ID: 15047641
[TBL] [Abstract][Full Text] [Related]
15. [Kidney disease and RAS].
Kimura G
Nihon Naika Gakkai Zasshi; 2006 Sep; 95(9):1756-61. PubMed ID: 17037311
[No Abstract] [Full Text] [Related]
16. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
[TBL] [Abstract][Full Text] [Related]
17. Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT).
Lambers Heerspink HJ; Weldegiorgis M; Inker LA; Gansevoort R; Parving HH; Dwyer JP; Mondal H; Coresh J; Greene T; Levey AS; de Zeeuw D
Am J Kidney Dis; 2014 Feb; 63(2):244-50. PubMed ID: 24210590
[TBL] [Abstract][Full Text] [Related]
18. [AT1 receptor antagonist lorsartan and organ protection. Managing hypertension a different way].
MMW Fortschr Med; 2006 Mar; 148(13):48-9. PubMed ID: 16642707
[No Abstract] [Full Text] [Related]
19. Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan.
Guo LL; Pan Y; Jin HM
Nephrol Dial Transplant; 2009 Jun; 24(6):1876-83. PubMed ID: 19164322
[TBL] [Abstract][Full Text] [Related]
20. The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.
Arredondo A; Burke TA; Carides GW; Lemus E; Querol J
Rev Invest Clin; 2005; 57(3):399-405. PubMed ID: 16187699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
